Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sichuan Goldstone Asia Pharmaceutical Inc (300434) Fair Value & Analysis

Industrials · CN · Market cap 3.7B CNY

Price¥8.96
Fair Value¥6.88
Upside-23.2%
Quality94/100
Evidence: High Range ¥4.80 – ¥8.60

Fair value as of: Jun 24, 2026

Analysis

Sichuan Goldstone Asia Pharmaceutical Inc (300434) currently trades at ¥8.96, while our model-based Fair Value estimate is ¥6.88 — implying the stock looks roughly 23.2% overvalued today. We read business quality at 94/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment. It also imports and exports spare parts, raw, and auxiliary materials. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 1962 and is based in Hangzhou, China.

Open the full interactive analysis →

Similar stocks

W.W. Grainger, Inc (GWW) -68% Fastenal Company (FAST) -55% Ferguson Enterprises Inc (FERG) -54% WESCO International, Inc (WCC) -65% Watsco, Inc (WSOB) -36% Toromont Industries Ltd (TMTNY) -47%

Frequently asked questions

Is Sichuan Goldstone Asia Pharmaceutical Inc (300434) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥6.88 versus a price of ¥8.96 — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 300434?
Our 21-model fair value for Sichuan Goldstone Asia Pharmaceutical Inc is ¥6.88 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥8.96.
What is the quality score of 300434?
Sichuan Goldstone Asia Pharmaceutical Inc has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.